Harald Engelhardt
Overview
Explore the profile of Harald Engelhardt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tarr J, Salovich J, Aichinger M, Jeon K, Veerasamy N, Sensintaffar J, et al.
J Med Chem
. 2024 Aug;
67(16):14370-14393.
PMID: 39102508
Myeloid cell leukemia 1 (Mcl-1) is a key regulator of the intrinsic apoptosis pathway. Overexpression of Mcl-1 is correlated with high tumor grade, poor survival, and both intrinsic and acquired...
2.
Lee E, Oh S, Lee Y, Kim J, Kim M, Kim T, et al.
Clin Cancer Res
. 2024 Feb;
30(8):1582-1594.
PMID: 38330145
Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) serve as the standard first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC). Despite the sustained clinical benefits achieved through...
3.
Wilding B, Scharn D, Bose D, Baum A, Santoro V, Chetta P, et al.
Nat Cancer
. 2022 Jul;
3(7):821-836.
PMID: 35883003
Oncogenic alterations in human epidermal growth factor receptor 2 (HER2) occur in approximately 2% of patients with non-small cell lung cancer and predominantly affect the tyrosine kinase domain and cluster...
4.
Tontsch-Grunt U, Traexler P, Baum A, Musa H, Marzin K, Wang S, et al.
Br J Cancer
. 2022 Apr;
127(3):577-586.
PMID: 35444289
Background: BET inhibitors have been tested in several clinical trials where, despite encouraging preclinical results, substantial clinical benefit in monotherapy remains limited. This work illustrates the translational challenges and reports...
5.
Zech M, Kopajtich R, Steinbrucker K, Bris C, Gueguen N, Feichtinger R, et al.
Ann Neurol
. 2021 Dec;
91(2):225-237.
PMID: 34954817
Objective: ATP synthase (ATPase) is responsible for the majority of ATP production. Nevertheless, disease phenotypes associated with mutations in ATPase subunits are extremely rare. We aimed at expanding the spectrum...
6.
Kazman P, Absmeier R, Engelhardt H, Buchner J
Nat Commun
. 2021 Nov;
12(1):6516.
PMID: 34764275
In antibody light chain (AL) amyloidosis, overproduced light chain (LC) fragments accumulate as fibrils in organs and tissues of patients. In vitro, AL fibril formation is a slow process, characterized...
7.
Graw J, Engelhardt H, Kusel K, Kruck D, Tinnefeld P, Sander J, et al.
Biospektrum (Heidelb)
. 2021 Jul;
27(4):400-405.
PMID: 34219984
No abstract available.
8.
Platzer G, Mayer M, Beier A, Bruschweiler S, Fuchs J, Engelhardt H, et al.
Angew Chem Int Ed Engl
. 2020 May;
59(35):14861-14868.
PMID: 32421895
While CH-π interactions with target proteins are crucial determinants for the affinity of arguably every drug molecule, no method exists to directly measure the strength of individual CH-π interactions in...
9.
Hofmann M, Mani R, Engelhardt H, Impagnatiello M, Carotta S, Kerenyi M, et al.
Mol Cancer Ther
. 2020 Feb;
19(4):1018-1030.
PMID: 32024684
Natural killer (NK) cells play a pivotal role in controlling cancer. Multiple extracellular receptors and internal signaling nodes tightly regulate NK activation. Cyclin-dependent kinases of the mediator complex (CDK8 and...
10.
Engelhardt H, Bose D, Petronczki M, Scharn D, Bader G, Baum A, et al.
J Med Chem
. 2019 Nov;
62(22):10272-10293.
PMID: 31689114
The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. While tumor responses to...